A Randomized Trial of Inhaled Versus Intravenous Steroids in Ventilator-Dependent Preterm Infants

Suchomski, Sandra J; Cummings, James J.

doi:10.1038/sj.jp.7210705

Cited by 23 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the trials demonstrated significant change on the BPD rate at 28 days or 36 weeks postmenstrual age. Multiple trials examined the effectiveness of inhaled steroids administered to ventilator dependent preterm infants after two weeks of life [45–48]. These approaches offered no advantage of aerosolized corticosteroids over systemic therapy.…”

Section: Steroidsmentioning

confidence: 99%

Current Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary Dysplasia

Tropea

Christou

2012

International Journal of Pediatrics

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is a major complication of preterm birth and has serious adverse long-term health consequences. The etiology of BPD is complex, multifactorial, and incompletely understood. Contributing factors include ventilator-induced lung injury, exposure to toxic oxygen levels, and infection. Several preventive and therapeutic strategies have been developed with variable success. These include lung protective ventilator strategies and pharmacological and nutritional interventions. These strategies target different components and stages of the disease process and they are commonly used in combination. The purpose of this review is to discuss the evidence for current pharmacological interventions and identify future therapeutic modalities that appear promising in the prevention and management of BPD. Continued improved understanding of BPD pathogenesis leads to opportunities for newer preventive approaches. These will need to be evaluated in the setting of current clinical practice in order to assess their efficacy.

show abstract

Section: Steroidsmentioning

confidence: 99%

Current Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary Dysplasia

Tropea

Christou

2012

International Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…Nevertheless, in the above-mentioned clinical studies [4, 77, 78], no differences between the methylprednisolone- and budesonide-treated groups were found. Similarly, inhaled GCs (beclomethasone) showed no priority to intravenous GCs (dexamethasone) in ventilator-dependent preterm newborns [72]. …”

Section: Glucocorticoidsmentioning

confidence: 99%

Glucocorticoids in the treatment of neonatal meconium aspiration syndrome

Mokrá

Mokrý

2011

Eur J Pediatr

View full text Add to dashboard Cite

Meconium aspiration syndrome is a serious neonatal disease with complex pathophysiology. With respect to the contribution of meconium-induced lung edema, inflammation and vasoconstriction on the course of the disease, glucocorticoids are increasingly used in the treatment of MAS despite the fact that principal questions on the choice of GCs derivative, mode of delivery and dosing have not been answered yet. To bring a complex insight into the topic, this article reviews the pathomechanisms of MAS, mechanisms of action of GCs, as well as the advantages and disadvantages of GCs administration in experimental models and newborns with MAS.

show abstract

“…34 Improvements in lung function were seen only after 7 days and not after 36 hr as with systemic treatment. 35 Suchomski et al 36 showed that by day three of therapy, the intravenous steroid group had significantly decreased ventilator and oxygen requirements compared to both inhalation groups (400 and 800 mcg/day beclomethasone). By day 14, however, all groups had similar reductions in ventilator and oxygen requirements.…”

Section: Inhaled Steroids: Influence On Lung Function and Ventilator mentioning

confidence: 99%

Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia

Pantalitschka

Poets

2006

Pediatr. Pulmonol.

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is one of the most common long-term complications and treatment challenges in preterm infants. Theoretically, inhaled corticosteroids may suppress pulmonary inflammation without causing systemic side-effects, while bronchodilators will improve airway resistance and thereby work of breathing. This article reviews current data on these drugs in BPD prevention or treatment. Trials published to date have not demonstrated that regular bronchodilator administration influences the incidence of BPD or improves long-term outcome. Inhaled steroids started before 2 weeks of age may improve rates of successful extubation and reduce the need for rescue systemic glucocorticoids, but have not been shown to reduce the incidence of BPD. Thus, their use cannot be generally recommended. The data currently available are not sufficient to give any clearer recommendation on the use of these drugs in infants at high risk of, or established, BPD.

show abstract

A Randomized Trial of Inhaled Versus Intravenous Steroids in Ventilator-Dependent Preterm Infants

Cited by 23 publications

References 21 publications

Current Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary Dysplasia

Current Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary Dysplasia

Glucocorticoids in the treatment of neonatal meconium aspiration syndrome

Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia

Contact Info

Product

Resources

About